Related Experiment Video
Updated: Aug 23, 2025

06:46
Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
Published on: August 4, 2018
12.3K
The Tree Drawing Test in Evolution: An Explorative Longitudinal Study in Alzheimer's Disease
Michelangelo Stanzani Maserati1, Marialaura Matacena2, Flavia Baccari1
1419170IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
American Journal of Alzheimer'S Disease and Other Dementias
|November 1, 2022
Summary
The Tree Drawing Test (TDT) shows Alzheimer
Area of Science:
- Neurology
- Neuropsychology
- Cognitive Science
Background:
- Alzheimer's disease (AD) poses a significant challenge in cognitive impairment diagnosis.
- Early detection and monitoring of AD progression are crucial for patient management.
Purpose of the Study:
- To investigate the longitudinal changes in the Tree Drawing Test (TDT) among individuals with Alzheimer's disease.
- To assess the utility of TDT parameters in tracking cognitive decline over time.
Main Methods:
- 33 Alzheimer's disease patients were assessed using the Mini Mental State Evaluation (MMSE) and TDT.
- The evolution of TDT parameters, specifically the trunk-to-crown (TC) index and space occupation (SO) index, was analyzed over time.
Main Results:
- A progressive reduction in the crown relative to the trunk was observed in TDT drawings.
- The trunk-to-crown (TC) index demonstrated a significant linear increase of 2.52 points per year.
- The space occupation (SO) index did not show a significant change, and no significant correlation was found between MMSE scores and TDT parameters.
Conclusions:
- The Tree Drawing Test (TDT) shows potential as a complementary tool for diagnosing cognitive impairment in Alzheimer's disease.
- TDT can aid in monitoring the progression of cognitive decline in AD patients over time.
Related Concept Videos
Alzheimer's Disease: Overview
626
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
626
Alzheimer's Disease: Treatment
246
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
246
Survival Tree
132
Survival trees are a non-parametric method used in survival analysis to model the relationship between a set of covariates and the time until an event of interest occurs, often referred to as the "time-to-event" or "survival time." This method is particularly useful when dealing with censored data, where the event has not occurred for some individuals by the end of the study period, or when the exact time of the event is unknown.
Building a Survival Tree
Constructing a...
Building a Survival Tree
Constructing a...
132

